2013 2013 3
3 313 31 2008 2009 2010 2011 2012 90,889 99,764 104,069 103,232 107,031 8,952 13,261 16,443 14,464 17,948 % 9.8 13.3 15.8 14.0 16.8 2,037 8,848 10,927 9,231 12,422 % 2.2 8.9 10.5 8.9 11.6 4,575 12,027 6,805 8,913 11,544 (4,229) 412 (1,806) (4,926) (7,187) 346 12,439 4,999 3,987 4,357 10,531 11,807 12,495 13,964 11,059 % 11.6 11.8 12.0 13.5 10.3 1,612 1,291 1,668 1,952 6,576 3,799 2,810 2,458 2,363 2,738 ROE % 2.1 8.8 10.1 8.0 10.0 ROA% 1.6 6.8 7.7 6.3 8.3 124,552 137,190 147,234 145,673 154,968 96,501 104,911 111,706 118,201 129,099 % 77.5 76.5 75.9 81.1 83.3 1 1 1,290.67 1,403.60 1,494.83 1,581.94 1,727.86 1 27.24 118.37 146.21 123.54 166.25 1 13.00 50.00 45.00 45.00 50.00 % 47.7 42.2 30.8 36.4 30.1 2012 10 11,070 3.7% 1.7 6 20.8%17924.1% 12434.6% ROE 10.0% 2.0
120,000 90,000 90,889 99,764 104,069 103,232 107,031 20,000 15,000 17,948 16,443 14,464 13,261 15,000 12,000 12,422 10,927 9,231 8,848 9,000 60,000 10,000 8,952 6,000 30,000 5,000 3,000 2,037 0 2008 2009 2010 2011 2012 0 2008 2009 2010 2011 2012 0 2008 2009 2010 2011 2012 ROE 1 12.0 84.0 83.3 180 166.25 90.0 10.1 10.0 146.21 9.0 8.8 8.0 82.0 80.0 81.1 120 47.7 118.37 123.54 60.0 6.0 78.0 77.5 76.5 60 42.2 30.8 36.4 30.1 30.0 3.0 2.1 76.0 75.9 27.24 0 2008 2009 2010 2011 2012 74.0 2008 2009 2010 2011 2012 0 2008 2009 2010 2011 20120 1.. 02... 04... 10... 18... 19... 20... 21... 22... 25... 26... CSR 28... 32... 34... 35... 36... 37... 38... 39... 1
1923 1977 1980 1923 1961 1980 NFLX 1992 1931 1962 1965 AP2 S 1981 1982 NFLX 1993 FLRX 1995 1940 1946 1967 1971 1974 HES 1976 HES 1977 1983 NFLX 1984 NFLX 1986 FLRX F. 1989 1991 1996 GFLX 1998 P&G 1999 2 1957 2 2013
HOPE100 Aim for Health Of People and our Enterprises HOPE100100 2023 HOPE100 2023 2000 2013 2000 1 2001 Kyorin USA, Inc. 100% 2002 Kyorin Europe GmbH 100% GFLX 2004 ActivX Biosciences, Inc. 100% 2005 100% 2006 1 2007 0.1mg 4mg 2008 5mg SkyePharmaFlutiform 500 2009 Merz Neramexane 2010 DS50% 2011 Almirall Aclidinium Bromide 0.1mg 2012 MSD 0.5% S.A. 2013 1g 3 3 3 3
HOPE100 1 HOPE100 1 StrategyOrganization Performance3 S O Strategy Organization P Performance 200 63 1,067 1,200 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 1 2 4 2013
HOPE100 HOPE100 1 2010HOPE100 No.1 20122013 3 20132014 390 HOPE100 2010 2023 HOPE100 12010 2015 2015 2013 7 2020 2021 2023 3 5
Q1 2012 Answer: 01 20126.0% 6% 2012 2012 10 1,070 313.7% 20.8% 179 4824.1% 2011 2012 2013 % 2015 368 396 408 12 3.2 400 215 191 187 4 2.0 240 180 176 186 10 5.6 190 63 75 84 9 13.4 100 1 MC PC 2015 2016 3 1,400200 6 2013
Answer: 02 3 MC1 Q2 2012 Answer: 03 2013 1,000 2012 9 KRP-108 2013 6 1g FC HOPE100 3 2020 2023 R&D 2015 1 Q3 HOPE 100 1 20152013 7
Q4 Answer: 04 NO.1 Q5 Answer: 05 2013 62 8 2013
Q6 Answer: 06 30% 30% 201230.1% 515020131 52 10 30.6% 2015 1,400 1,200 * 200 200 * Q7 Answer: 07 90100 10HOPE100 HOPE100 9
MR http://www.kyorin-rmd.co.jp/ http://www.drprogram.co.jp/ http://www.kyorin-pharm.co.jp/ http://www.kyorin-ms.co.jp/ http://www.kyorin-fc.co.jp/ 2012 10 MSD 10 2013
HOPE100 12013 HOPE100 1 P.12 P.14 GMP Good Manu- facturing Practice P.16 FC MR 11
1 1 2 3 3 12 2013
R&D OJT R&D 3 13
GMP Good Manufacturing Practice 4 2012 10 4 14 2013
3 OJT QDC* * QDC QQualityDDeliveryCCost 15
MR FCMR MR MR MRMR MRMR 2012 MRPC MR MR KRP-108 16 2013
1g 2013 MR 2013 MR MR MR MR 2 3 MR MR5 MR MR FC MR 17
FC KRP-108KRP-AB1102KRP-AB1102F3 COPD COPD KRP- 108KRP-AB1102 KRP-AB1102F R&D KRP-108 KRP-108 KRP-108 FC 4 No.1 FC KRP-AM1977Y KRP-AM1977X KRP-AB1102F KRP-AB1102 KRP-108 COPD 1,000 1,400 4,100 77,000 1,700 MR750 18 2013
500 400 368 396 408 100 75 63 75 84 300 200 50 100 5mg10mg 0 4mg5mg 2011 2012 2013 0.1mg OD 0.1mg 25 2011 2012 2013 0 250 200 215 191 187 200 150 180 176 186 150 100 100 250mg500mg 50%5% DS 50% 50 0 2011 2012 2013 250mg500mg 1g1g 50 0 2011 2012 2013 10mg FUL 1963 2012 2012 7 19
FC 2008 5KRP-108 KRP-209 KRP-AB1102KRP- AB1102F4 FC MSD LG S.A. SPIMACO* * SPIMACO Saudi Pharmaceutical Industries & Medical Appliances Corporation 20 2013
2013 7 30 Ph KRP-108 ICS 2LABA 08 4 Ph12 3 12 9 KRP-AB1102 COPD M3 1 21 Genuair 11 2 12 9 ( ) MSD 13 4 KRP-108 09 312 9 KRP-AB1102 12 912 12 POCPhPh KRP-209 NMDA 09 11 11 8 KRP-AB1102F M3LAMA LABA 11 2 12 5 KRP-203 IBD S1P 06 2 IDB 10 11 13 3 KRP-AM1977X KRP-AM1977Y MRSA 11 8 12 7 KRP-209 Ph KRP-AB1102F PhPh KRP-203 IBD S1P 06 2IDB 10 11 POC 10 12 21
6 5 10 2 HOPE100 CSR 1. 10 4 2013 6 25 22 2013
1 2013 6 2 235 2. http //www.kyorin-gr.co.jp/ company/governance.shtml 3. 6 23 B R B R 3 23
12 10 4. 5. 6170 230200 316 7. 3 1 8. 1652 4591 9. 3092 31 32 6. 15 HOPE100 24 2013
2013 6 25 25
CSR CSR 2010 8 1 1. 2. 3. 2006 3 1. 2. 3. 11 1. 2821 2. 3. PRTR CO2 20,000 15,000 10,000 5,000 0 2008 2009 2010 2011 2012 * 2008 * 2009 2012 26 2013
4. NOx SOx 5. ph BOD SS 6. 7. 8. OHSAS180012004 2005ISO14001 OHSAS18001 2008ISO14001 2009 OHSAS18001 1. 2. 2012 212 2013 1. 40 2012 10 2 2. 2012 110,484 2.8kg 3. 2011 27
120,000 90,000 60,000 90,889 99,764 104,069 103,232 107,031 30,000 18,000 12,000 6,000 0 0 2008 n n n n 2008 2.1 2,037 2008 2009 2010 2011 2012 40,000 30,000 20,000 10,000 0 9.8 8,952 n 13.3 13,261 n n 8.8 8,848 15.8 16,443 10.1 10,927 n ROE 14.0 14,464 2009 2010 2011 2012 8.0 12,422 9,231 16.8 17,948 ROE 10.0 2009 2010 2011 2012 % 20.0 15.0 10.0 5.0 0 % 12.0 8.0 4.0 0 2012 2012 4 6.0% 6% 2012 1,070 313.7% 2012 4 2012 10 1 882 862.7% S.A. 2012 10 2013 2 1 24 0019.1% 2012 100 95 16.6% 43 79 9.8% 1,051 624.5% 18 6927.5% 37.5% 1.7 5 91 28 2013
110 5920.8% 489 495.6% 179 4824.1% 2.816.8% % 60.0 2011 2012 (%) 103,232 107,031 3,798 3.7 36,926 40,133 3,207 8.7 66,306 66,897 591 0.9 51,842 48,949 (2,892) (5.6) 13,964 11,059 (2,904) (20.8) 14,464 17,948 3,484 24.1 879 790 (88) (10.1) 67 62 (5) (8.5) 15,262 18,603 3,340 21.9 9,231 12,422 3,190 34.6 40.0 20.0 0 40.5 37.6 36.1 35.8 37.5 2008 2009 2010 2011 2012 2011 2012 (%) 9,231 12,422 3,191 34.6 640 1,843 1,203 188.0 150,000 120,000 90,000 96,501 129,099 118,201 111,706 104,911 9,871 14,265 4,394 44.5 60,000 1 30,000 124 2234.6% 1 166 2542 71 0 2008 2009 2010 2011 2012 84 14 8 8092 95 1,549 68 16 3258 68 % 90.0 77.5 76.5 75.9 81.1 83.3 108 981,290 99 60.0 83.3%2.2 ROE ROE 20122.0 10.0% 30.0 0 2008 2009 2010 2011 2012 2011 2012 (%) 99,850 108,265 8,414 8.4 45,822 46,702 880 1.9 145,673 154,968 9,295 6.4 23,385 22,897 (487) (2.1) 4,086 2,970 (1,115) (27.3) 27,471 25,868 (1,603) (5.8) 117,931 126,985 9,054 7.7 269 2,113 1,843 685.5 118,201 129,099 10,898 9.2 145,673 154,968 9,295 6.4 29
20,000 10,000 10,000 0 12,027 12,439 11,544 8,913 6,805 4,575 4,999 3,987 4,357 346 (4,229) 2008 412 n n n (1,806) (4,926) (7,187) 2009 2010 2011 2012 2012 115 44 186 3 27 38 14 8010 104 86 46 23 71 87 59 9559 72 35 124 2 68 53 51 32 16 7533 57 6 67 225 43 45 140 00 110 0037 2011 2012 (%) 8,913 11,544 2,631 29.5 (4,926) (7,187) (2,261) (45.9) (7,412) (5,132) 2,280 30.8 23,210 22,543 (667) (2.9) 2013 HOPE100 12010 2015 4 2013 2012 10 12110 2013 2012 2013 (%) 107,031 113,000 5.6 17,948 18,600 3.6 12,422 12,700 2.2 30 2013
1. 2. 3. 6. 7. 8. 9. PL 4. 5. 10. 11. 12. IT IT 31
20122013 3 31 2011 2012 21,615 21,370 45,067 46,555 7,372 11,667 11,016 11,405 632 837 9,089 7,694 2,340 2,773 2,774 6,013 (58) (53) 99,850 108,265 28,222 30,306 (18,888) (19,790) 9,333 10,515 15,827 16,668 (13,331) (13,897) 2,495 2,770 1,619 2,466 149 332 (65) (78) 83 253 39 1,071 6,690 7,071 (5,719) (5,940) 971 1,131 14,544 18,209 192 64 11 7 642 844 846 916 26,040 24,552 24 19 3,144 1,438 1,642 1,690 (421) (123) 30,431 27,577 45,822 46,702 145,673 154,968 32 2013
2011 2012 9,043 8,556 3,159 1,523 39 81 2,111 3,356 3,110 3,327 52 43 65 45 5,802 5,962 23,385 22,897 316 251 45 184 2,949 1,938 32 33 743 562 4,086 2,970 27,471 25,868 700 700 4,752 4,752 112,797 121,856 (318) (323) 117,931 126,985 537 2,293 (267) (180) 269 2,113 118,201 129,099 145,673 154,968 33
20122013 3 31 2011 2012 103,232 107,031 36,926 40,133 66,306 66,897 51,842 48,949 14,464 17,948 176 104 164 204 269 268 26 39 243 174 879 790 48 38 17 17 1 6 67 62 15,275 18,676 21 0 1 25 22 25 27 98 7 0 0 34 98 15,262 18,603 5,179 5,869 851 312 6,031 6,181 9,231 12,422 9,231 12,422 20122013 3 31 2011 2012 9,231 12,422 672 1,738 (34) 87 2 18 640 1,843 9,871 14,265 9,871 14,265 34 2013
20122013 3 31 2011 2012 700 700 700 700 4,752 4,752 4,752 4,752 106,928 112,797 (3,362) (3,362) 9,231 12,422 5,868 9,059 112,797 121,856 (304) (318) (13) (4) (13) (4) (318) (323) 112,076 117,931 (3,362) (3,362) 9,231 12,422 (13) (4) 5,854 9,054 117,931 126,985 (137) 537 674 1,756 674 1,756 537 2,293 (232) (267) (34) 87 (34) 87 (267) (180) (370) 269 640 1,843 640 1,843 269 2,113 111,706 118,201 (3,362) (3,362) 9,231 12,422 (13) (4) 640 1,843 6,494 10,898 118,201 129,099 35
20122013 3 31 2011 2012 15,262 18,603 2,363 2,738 147 128 (7) (302) (110) 211 (816) (1,010) 8 1 (26) (39) (340) (308) 48 38 5 98 (1) (25) 7 (2,474) (1,480) (374) 800 (1,809) (486) (238) (144) 3,451 (2,956) 15,098 15,865 369 323 (48) (21) (6,505) (4,623) 8,913 11,544 (822) (1,328) 1,057 1,139 (799) (5,995) 2,402 (1,686) (5,972) 25 0 (357) (344) (7,427) (3,501) 5,121 6,853 (36) (441) (4,926) (7,187) (3,840) (1,675) (43) (70) 200 360 (328) (386) (30) (12) (2) (3,357) (3,357) (7,412) (5,132) (29) 108 (3,454) (667) 26,665 23,210 23,210 22,543 36 2013
20122013 3 31 2011 2012 9,140 14,938 8,259 10,112 66 79 668 2,584 2,000 133 138 12 22 80,958 84,649 245 871 198 512 80,514 83,265 90,099 99,587 586 466 8 7 594 474 89,504 99,112 89,504 99,112 90,099 99,587 20122013 3 31 2011 2012 6,139 15,654 2,650 2,476 3,489 13,178 33 38 3,523 13,126 7 185 3,515 13,031 3 27 97 29 3,414 12,973 37
2013 6 25 2013 7 43 17100% 101-8311 4-6 4 88100% 160-00236-25-13 12100% 920-0017287-1 2 51100% 160-00236-25-13 4 50100% 528-0061 1-4 Kyorin USA, Inc. 50 US$ 100% 500 Frank W. Burr Boulevard, Teaneck, New Jersey 07666, U.S.A Kyorin Europe GmbH 5 EURO 100% Kaiserstrasse 8, 60311 Frankfurt am Main, Germany ActivX Biosciences, Inc. 1US$ 100% 11025 N. Torrey Pines Rd., La Jolla, CA 92037, U.S.A 4 1129.2% 103-00234-2-2 38 2013
2013 3 31 101-8311 4-6 03-3525-4700 URL http://www.kyorin-gr.co.jp/ 331958 7 74,947,628 5,276 6.67% 4.91% 3.90% 3.86% 3.66% 3.53% 3.00% 2.97% 2.60% 2.60% 103-00281-2-1 03-3278-8111 39
KYORIN Holdings, Inc. 101-8311 4-6 IR TEL 03-3525-4707 FAX 03-3525-4777 E-mail http://www.kyorin-gr.co.jp/contact/ URL http://www.kyorin-gr.co.jp/ Printed in Japan